Sudarshan Pharma Industries Ltd (SUDARSHAN) fair value: what the stock is really worth
As of Oct 5, 2026: fair value of Sudarshan Pharma Industries Ltd ₹15.34, price ₹37.10, upside -58.7%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
42‑month range ₹5.10 – ₹51.83 · fair‑value band ₹10.74 – ₹19.83 · the ₹37.10 price screens above the ₹15.34 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Sudarshan Pharma Industries in your weekly email
Every Wednesday you see whether Sudarshan Pharma Industries is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sudarshan Pharma Industries Limited manufactures and sells specialty chemicals and intermediates for pharma, agro chemicals, coating, and various other industries in India. The company also focuses on manufactures active pharmaceuticals ingredients and vitamins manufacturing.
Show more
Sudarshan Pharma Industries Limited manufactures and sells specialty chemicals and intermediates for pharma, agro chemicals, coating, and various other industries in India. The company also focuses on manufactures active pharmaceuticals ingredients and vitamins manufacturing. It also offers fine chemicals, solvents, agro chemicals, finish lubricants, inks, food colors, leather chemicals, oil field chemicals, lubricant specialties, paints and coatings, paper chemicals, personal and community hygiene products, pigments, polymers and additives, press room chemicals, sugar chemicals, textile chemicals, water treatment chemicals, rust preventives, metalworking fluids, PU additives, and other specialty chemicals. In addition, the company offers antibiotics, antifungal, anthelmintic medications, antihypertensive, anti-diabetic drugs, analgesics, neurotonics, antihistamines, and cough syrups, as well as manufactures and supplies chemicals and solvents. Further, it engages in the contract manufacturing and outsourcing and supply of generic pharma formulation and medicines to healthcare institution, government, NGO, and hospitals. The company also exports its products to the United Kingdom, Australia, Uzbekistan, Syria, Oman, Taiwan, the Middle East, and North Africa regions. Sudarshan Pharma Industries Limited was incorporated in 2008 and is headquartered in Mumbai, India.
Stock analysis
Sudarshan Pharma Industries Ltd (SUDARSHAN) currently trades at ₹37.10, while our model-based Fair Value estimate is ₹15.34, 58.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹20.77 per share, and 1 of the 14 models we run sit above the ₹37.10 price.
Bear case: the Asset-Based group reads lowest at ₹4.20, and 13 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹10.74 (bear) to ₹19.83 (bull), the price of ₹37.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Sudarshan Pharma Industries Ltd reported revenue of ₹7.0B in FY2026 versus ₹3.6B in FY2022, a compound +18.5%/yr. Reported net income was ₹233M in FY2026, compounding +45.2%/yr from FY2022.
Key figures
Market cap ₹8.9B (≈ $92.7M) · P/E ratio 38.2 · P/S ratio 1.27 · EPS (TTM) ₹0.9700 · Net margin 3.3% · Return on equity 16.2% · Return on assets (EBIT) 7.5% · Operating margin 8.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 12% below its 52-week high and 93% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −24% fair-value upside, at −59%, SUDARSHAN screens richer than that median.
Fair Value models
Bear ₹10.74Fair Value ₹15.34Bull ₹19.83
Price ₹37.10 · Upside -58.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.4996 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+39.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.1%
’22
’23
’24
’25
’26
What shareholders gained per year (last 3 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+47.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+47.4%
Dividend (yield on the price)0.0%
Profit margin 2022 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 7%
2026 sits 103% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
Compare Sudarshan Pharma Industries Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Chemicals · 342 stocks
Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score36 · Bottom 25%
Fair Value upside−58.7% · Bottom 25%
Profitability
Return on equity (TTM)16.2% · Top 25%
Return on assets5.7% · Above median
Net margin (TTM)3.3% · Below median
Operating margin (TTM)8.7% · Below median
Growth and dividend
Revenue growth36.7% · Top 25%
Balance sheet
Debt / equity0.18× · Above median
Valuation Multiplesvs Chemicals median · lower = cheaper
P/E (TTM)38.2× · Pricier than median
P/B5.71× · Priciest 25%
P/S (TTM)1.27× · Pricier than median
EV/EBITDA17.9× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 2
FUTURE (revenue growth)100· sector 64
PAST (return on equity)65· sector 23
HEALTH (low debt)91· sector 94
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sudarshan Pharma Industries Ltd (SUDARSHAN) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ₹15.34 versus a price of ₹37.10, about −59% upside (overvalued).
What is the fair value of SUDARSHAN?
Our model-based fair value for Sudarshan Pharma Industries Ltd is ₹15.34 (as of Oct 3, 2026), built from audited fundamentals. The current price: ₹37.10.
What is the quality score of SUDARSHAN?
Sudarshan Pharma Industries Ltd has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sudarshan Pharma Industries Ltd (SUDARSHAN)?
Our model-based price target is the fair value of ₹15.34 (as of Oct 3, 2026) from 14 valuation models. Cautious scenario ₹10.74, optimistic scenario ₹19.83. It is a calculation from audited fundamentals, not an analyst target.
What is the Sudarshan Pharma Industries Ltd stock forecast for 2026?
Our models put fair value at ₹15.34, about −59% upside versus a price of ₹37.10 (overvalued). Cautious scenario ₹10.74, optimistic scenario ₹19.83. The calculation is refreshed regularly with new filings.
What is the revenue of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
Sudarshan Pharma Industries Ltd reported trailing-twelve-month revenue of about ₹7.0B (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sudarshan Pharma Industries Ltd it is ₹15.34 per share (as of Oct 3, 2026), against a price of ₹37.10. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Sudarshan Pharma Industries Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, SUDARSHAN trades above its calculated fair value: price ₹37.10, fair value ₹15.34, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SUDARSHAN?
No. The price is what the market pays today (₹37.10); the fair value is what the company's own numbers justify (₹15.34). For Sudarshan Pharma Industries Ltd the two are ₹21.76 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sudarshan Pharma Industries Ltd worth?
The market values Sudarshan Pharma Industries Ltd at about ₹8.9B (market capitalisation, as of Oct 3, 2026). Per share that is ₹37.10; our models calculate a fair value of ₹15.34 per share.
What do the bullish and bearish scenarios say about SUDARSHAN?
Our models span a range for Sudarshan Pharma Industries Ltd: cautious scenario ₹10.74, base ₹15.34, optimistic ₹19.83 per share (as of Oct 3, 2026, price ₹37.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SUDARSHAN?
Sudarshan Pharma Industries Ltd trades at a price-to-earnings ratio of 38.2 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹15.34 is built from several models across several years. Other multiples: P/B 5.7, P/S 1.3, EV/EBITDA 17.9.
How solid is the balance sheet of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
Balance-sheet figures for Sudarshan Pharma Industries Ltd (as of Oct 3, 2026): return on equity 16.2%, debt of 0.18 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is SUDARSHAN from its 52-week high?
Sudarshan Pharma Industries Ltd trades at ₹37.10, about 12% below its 52-week high of ₹42.31 and 93% above the low of ₹19.23 (as of Oct 5, 2026). Distance from the high says nothing about value: that is what the fair value of ₹15.34 is for.
Which stocks are comparable to Sudarshan Pharma Industries Ltd?
From the same area (Basic Materials) we also value BASF SE, Ningxia Baofeng Energy Group, Dow Inc, Hengli Petrochemical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sudarshan Pharma Industries Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price ₹37.10, calculated fair value ₹15.34 (−59%), Quality Score 36/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SUDARSHAN calculated?
We run Sudarshan Pharma Industries Ltd through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹15.34, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1 % above its aggregate fair value. Sudarshan Pharma Industries Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
The closing price on Oct 5, 2026 was ₹37.10. Our model-based fair value is ₹15.34, about −59% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sudarshan Pharma Industries Ltd right now?
The price sits above even our optimistic bull case (₹19.83). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹10.74 to ₹19.83) leaves room in how you read the outcome.
Key figures of Sudarshan Pharma Industries Ltd
How large is the market capitalisation of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
The market capitalisation of Sudarshan Pharma Industries Ltd is ₹8.9B (≈ $92.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
The price-to-sales ratio of Sudarshan Pharma Industries Ltd is 1.27 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
Earnings per share at Sudarshan Pharma Industries Ltd are ₹0.9700 (price ÷ EPS = P/E 38.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
The net margin of Sudarshan Pharma Industries Ltd is 3.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
The return on equity (ROE) of Sudarshan Pharma Industries Ltd is 16.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
On an EBIT basis the return on assets of Sudarshan Pharma Industries Ltd is 7.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sudarshan Pharma Industries Ltd (SUDARSHAN)?
The operating margin of Sudarshan Pharma Industries Ltd is 8.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sudarshan Pharma Industries Ltd (SUDARSHAN)?
Revenue at Sudarshan Pharma Industries Ltd is growing +36.7% versus a year earlier (3y avg +15.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sudarshan Pharma Industries Ltd (SUDARSHAN)?
Earnings per share at Sudarshan Pharma Industries Ltd are growing +62.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sudarshan Pharma Industries Ltd (SUDARSHAN) generate?
The free cash flow of Sudarshan Pharma Industries Ltd is −₹714M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sudarshan Pharma Industries Ltd (SUDARSHAN) carry?
The net debt of Sudarshan Pharma Industries Ltd is ₹2.8B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sudarshan Pharma Industries Ltd in the live analysis
One click puts Sudarshan Pharma Industries Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
